Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 study of CS-7017 in combination with FOLFIRI in metastatic colorectal cancer
jRCT2080221193Phase 1
- Sponsor
- Daiichi Sankyo Co., Ltd.
- Start
- Aug 2010
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of efatutazone in metastatic colon cancer (mCRC), sponsored by Daiichi Sankyo Co., Ltd. Primary endpoint: Safety and tolerability of CS-7017 in combination with FOLFIRI.
02
Drugs
efatutazone
03
Conditions
metastatic colon cancer (mCRC)
Beyond the preview
Go deeper on jRCT2080221193.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080221193.